Researchers discover that topical treatment improves chronic plaque psoriasis

[Joachim]

Researchers at the Icahn School of Medicine report that roflumilast cream (ARQ-151), which contains a highly potent, selective phosphodiesterase-4 (PDE4) inhibitor demonstrated significant improvements in patients with psoriasis signs and symptoms in as early as two weeks. The phase 2b trial results showed that when patients with plaque psoriasis applied topical roflumilast once-daily they reported clear skin as well as improvement in itch and burden of disease. The results of the paper were published online today in the New England Journal of Medicine.

Link naar het originele artikel